Table 4.
Summary of selected articles.
| Author/year/place of publication | Objective | n | Tests | Hearing loss classification | Results | Conclusion |
|---|---|---|---|---|---|---|
| Einarsson et al.27, 2010, Sweden | Investigate long-term hearing impairment in subjects who received platinum-based chemotherapy in childhood or adolescence. | 15 | PTA (0.125, 0.25, 0.5, 1, 2, 3, 4, 6 e 8 kHz) | Brock et al. (1991) | The results show that hearing loss, in subjects with ototoxicity, increased after the end of the treatment, also including the lower frequencies. The greatest deterioration in hearing thresholds, up to 55 dB HL, was found at frequencies above 2 kHz. | The conclusion of this study is that children and adolescents treated with platinum-based chemotherapy should undergo regular follow-up audiometric tests, also many years after the end of treatment. In addition, self-reported hearing impairment assessments should be made during and after chemotherapy |
| Tympanometry Speech audiometry | ||||||
| Measurement of the handicap level (Hearing measurement scale — HMS) | ||||||
| Clemens et al.28, 2016, Netherlands | To determine the frequency and determinants of ototoxicity in a large multicenter cohort of child cancer survivors who received platinum, but not cranial irradiation as treatment. | 451 | PTA (0.25, 0.5, 1, 2, 4 e 8 kHz) | Münster (Schmidt et al., 2007) | The general frequency of ototoxicity was 42%, observed in 45% of those treated with cisplatin, in 17% of those treated with carboplatin, and in 75% of those who received both drugs. The lowest age at the time of diagnosis, the highest total cumulative dose of cisplatin, and the concomitant treatment with furosemide were associated with ototoxicity. | Treatment with a higher total cumulative dose of cisplatin, younger age at diagnosis, and concomitant use of furosemide, independently, are associated with an increased risk of ototoxicity in subjects treated with platinum in childhood. |
| Clemens et al.29, 2017, Netherlands | To study the reversibility of ototoxicity after discontinuing treatment in a cohort of subjects treated with platinum with hearing loss at the end of cancer treatment. | 168 | PTA (0.25, 0.5, 1, 2, 4 e 8 kHz): age ≥5 years | Münster (Schmidt et al., 2007) | Of the 168 participants, 61 (36.3%) had hearing loss after completing chemotherapy, and none of these subjects showed improvement in hearing function until 28.8 years after discontinuing treatment. | Ototoxicity after platinum treatment may be irreversible and monitoring, as well as longitudinal clinical haring care, is required. |
| Conditioned play audiometry: age between 2 and 5 years. | ||||||
| VRA in children aged 6 months to 2 years. |